Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798157 | 0.99 | SLC6A9 (0.61) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL3538639 | 0.95 | SLC6A9 (0.56) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL3536275 | 0.82 | GPR88 (0.57) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL1795284 | 0.80 | SLC6A9 (0.76) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL1795282 | 0.80 | SLC6A9 (0.76) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL26840798 | 0.78 | SLC6A9 (0.73) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL3289063 | 0.77 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4589243 | 0.76 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL4589246 | 0.76 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL1689516 | 0.76 | SLC6A9 (1.00) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700585-B2 | Derivatives of N-[phenyl(pyrrolidine-2-YL)methyl]benzamide and N-[(azepan-2-YL) phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-20 | — | — | US | disclosed |
| US-7226917-B2 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation, and use in treatment of schizophrenia | SANOFI-AVENTIS (FR) | 2007-06-05 | — | — | US | disclosed |
| CN-1882534-A | Derivatives of N- [ phenyl (2-pyrrolidinyl) methyl ] benzamide and N- [ (2-azepanyl) phenylmethyl ] benzamide, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2006-12-20 | — | — | CN | disclosed |
| US-20060223802-A1 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | disclosed |
| EP-1680400-A2 | DERIVATIVES OF N-[ PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[ (AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005037785-A2 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223802-A1 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SNCA, CHRNA10, CHRNA5 | SLC6A9 3907/4885SLC6A3 1410/4885SLC6A2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.